Aileron Therapeutics, Inc. (ALRN)

NASDAQ: ALRN · IEX Real-Time Price · USD
1.47
-0.05 (-3.29%)
At close: Oct 2, 2023, 4:00 PM
1.54
+0.07 (4.76%)
After-hours: Oct 2, 2023, 7:03 PM EDT
-3.29%
Market Cap 6.68M
Revenue (ttm) n/a
Net Income (ttm) -17.48M
Shares Out 4.54M
EPS (ttm) -3.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,927
Open 1.50
Previous Close 1.52
Day's Range 1.45 - 1.58
52-Week Range 1.12 - 5.64
Beta 2.12
Analysts n/a
Price Target n/a
Earnings Date Oct 31, 2023

About ALRN

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients wi... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 29, 2017
Employees 6
Stock Exchange NASDAQ
Ticker Symbol ALRN
Full Company Profile

Financial Performance

Financial Statements

News

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mu...

7 months ago - GlobeNewsWire

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

10 months ago - GlobeNewsWire

Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022 Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022

11 months ago - GlobeNewsWire

Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

11 months ago - GlobeNewsWire

Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patien...

1 year ago - GlobeNewsWire

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

BOSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patie...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patie...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patie...

1 year ago - GlobeNewsWire

Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

1 year ago - GlobeNewsWire

Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

1 year ago - GlobeNewsWire

Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting

Aileron Therapeutics (NASDAQ: ALRN) announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing treatment with fi...

1 year ago - Benzinga

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

BOSTON, June 29, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patien...

1 year ago - GlobeNewsWire

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patient...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patient...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patient...

1 year ago - GlobeNewsWire

Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patient...

1 year ago - GlobeNewsWire

Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patient...

1 year ago - GlobeNewsWire

Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations

BOSTON, April 21, 2022 (GLOBE NEWSWIRE) --  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more pati...

1 year ago - GlobeNewsWire

Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

BOSTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save mor...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effecti...

1 year ago - GlobeNewsWire

Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective...

1 year ago - GlobeNewsWire

Aileron Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patien...

1 year ago - GlobeNewsWire

Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs

BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a membe...

1 year ago - GlobeNewsWire

Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patient...

2 years ago - GlobeNewsWire